4dx asx shares surged 38% in early trade Wednesday morning ET after 4DMedical Ltd announced deployment of its CT: VQ technology at the Mayo Clinic in the United States. Investors pushed the ASX 300 stock to a record-high of $6. 40 as the Mayo Clinic has entered an agreement to use CT: VQ for ventilation and perfusion analysis. Company management framed the move as strategically important even though the initial agreement is not financially material.
4dx Asx surge: market reaction and deal details
The market reaction was immediate: the ASX 300 stock jumped 38% to a record intraday price, driven by news of the Mayo Clinic deployment. 4DMedical said the Mayo Clinic will initially focus the deployment on integrating CT: VQ into clinical workflows and allowing clinicians to evaluate the technology across a range of use cases. Management highlighted the Mayo Clinic’s adoption as one of the most significant endorsements of the technology to date and noted that, while the initial agreement is not financially material, its strategic value could be substantial as clinicians gain confidence.
The announcement also brings the company to six major deployments for CT: VQ within approximately seven months of receiving FDA clearance in September 2025. The other institutions named among the deployments are Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, and the University of Miami. The rapid sequence of deployments underscores rising institutional uptake of the CT: VQ system across leading U. S. hospitals.
Clinical rollout, capabilities and reactions
The company emphasized practical advantages of CT: VQ that have driven interest from large health systems. CT: VQ offers ventilation and perfusion analysis while eliminating the need for radioisotopes and contrast agents, provides high-resolution imaging, and integrates into existing CT workflows. The deployment at the Mayo Clinic is intended to let clinicians assess those capabilities across multiple clinical settings and use cases.
4DMedical management said the Mayo Clinic deployment could become a key reference site that supports broader commercial adoption as clinicians develop confidence in the technology. The company placed the deployment in a wider roll-out context, citing a cluster of major institutional adoptions since the FDA clearance in September 2025, which it presented as evidence of accelerating demand for its respiratory imaging solution.
What’s next
In the coming weeks and months, attention will focus on how the Mayo Clinic integrates CT: VQ into routine clinical workflows and what findings clinicians report from early evaluations. Investors will watch for further commercial milestones and additional deployments that might follow a successful evaluation at a major referral center. The market reaction on Wednesday morning ET signals heightened investor interest, and 4dx asx will remain in focus as the company and clinical partners document early clinical experience and adoption pathways.
